# Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer

> **NCT03744793** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 18 (actual)

## Conditions studied

- Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant
- Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation
- Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation
- Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant
- Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant
- Metastatic Urothelial Carcinoma
- MTAP Negative

## Interventions

- **DRUG:** Avelumab
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT03744793
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-04-11
- **Primary completion:** 2027-01-31
- **Final completion:** 2027-01-31
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2026-01-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03744793

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03744793, "Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03744793. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*